The approval of dual GLP-1/GIP receptor agonists for the treatment of T2D in 2022 has spurred even greater excitement about the potential benefits of these drugs for dementia and many other chronic diseases and health conditions, including prediabetes and obesity
Keller A, Rimestad ML, Friis Rohde J, Holm Petersen B, Bruun Korfitsen C, Tarp S, et al
The expectation was that nothing would happen
If your dose requires more than 1.5mL, the pool of liquid under your tongue becomes too large to maintain without swallowing
FSA/HSA Eligible, fda-approved, backed by clinical studies, easy-to-use Starting at $1,299.00 FSA/HSA Eligible, dual-action medication, expert guidance, highly effective Starting at $1,299.00 FSA/HSA Eligible, targeted for weight management, doctor-prescribed, proven effective Starting at $1,799.00